Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model blood diseases in vitro and for transplantation. Together with the laboratories of Professor Ed Stanley (Immune Development group) and Dr Elizabeth Ng (Blood Development group) at MCRI, Prof Elefanty has made important contributions to the generation of genetically modified human stem cell lines in which lineage-specific fluorescent reporters allow monitoring of differentiation.
After training as a physician, Professor Elefanty completed a PhD in leukaemogenesis at the Walter and Eliza Hall Institute of Medical Research supervised by Professor Suzanne Cory. He subsequently worked on globin gene regulation with Professor Frank Grosveld at the National Institute for Medical Research in Mill Hill, London before returning to the Hall Institute to pursue interests in developmental haematopoiesis and the differentiation of mouse embryonic stem cells.
He moved to Monash University in 2002 to initiate studies with human embryonic stem cells. In 2013, his laboratory relocated to the Murdoch Children’s Research Institute. In collaboration with Dr Elizabeth Ng and Prof Ed Stanley, he has focused on haematopoietic differentiation of human pluripotent stem cells.
Professor Elefanty holds active collaborations with:
• Professor Ed Stanley, Immune Development Laboratory, Murdoch Children's Research Institute
• Dr Elizabeth Ng, Blood Development Laboratory, Murdoch Children's Research Institute
• Professor Constanze Bonifer, Institute of Cancer and Genomic Sciences, University of Birmingham
• Professor Hanna Mikkola, Department of Molecular, Cell and Developmental Biology University of California
Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model...
Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model blood diseases in vitro and for transplantation. Together with the laboratories of Professor Ed Stanley (Immune Development group) and Dr Elizabeth Ng (Blood Development group) at MCRI, Prof Elefanty has made important contributions to the generation of genetically modified human stem cell lines in which lineage-specific fluorescent reporters allow monitoring of differentiation.
After training as a physician, Professor Elefanty completed a PhD in leukaemogenesis at the Walter and Eliza Hall Institute of Medical Research supervised by Professor Suzanne Cory. He subsequently worked on globin gene regulation with Professor Frank Grosveld at the National Institute for Medical Research in Mill Hill, London before returning to the Hall Institute to pursue interests in developmental haematopoiesis and the differentiation of mouse embryonic stem cells.
He moved to Monash University in 2002 to initiate studies with human embryonic stem cells. In 2013, his laboratory relocated to the Murdoch Children’s Research Institute. In collaboration with Dr Elizabeth Ng and Prof Ed Stanley, he has focused on haematopoietic differentiation of human pluripotent stem cells.
Professor Elefanty holds active collaborations with:
• Professor Ed Stanley, Immune Development Laboratory, Murdoch Children's Research Institute
• Dr Elizabeth Ng, Blood Development Laboratory, Murdoch Children's Research Institute
• Professor Constanze Bonifer, Institute of Cancer and Genomic Sciences, University of Birmingham
• Professor Hanna Mikkola, Department of Molecular, Cell and Developmental Biology University of California
Top Publications
Arasaratnam, D, Bell, KM, Sim, CB, Koutsis, K, Anderson, DJ, Qian, EL, Stanley, EG, Elefanty, AG, Cheung, MM, Oshlack, A, et al.
The role of cardiac transcription factor NKX2-5 in regulating the human cardiac miRNAome..
Sci Rep
9(1)
:
15928
2019
view publication
Dong, L, Reljic, B, Cheung, JG, Ng, ES, Lindqvist, LM, Elefanty, AG, Vaux, DL, Tran, H.
In the absence of apoptosis, myeloid cells arrest when deprived of growth factor, but remain viable by consuming extracellular glucose..
Cell Death Differ
26(10)
:
2074 -2085
2019
view publication
Howden, S, Hosseini Far, H, Motazedian, A, Elefanty, AG, Stanley, EG, Lamandé, SR, Bateman, JF.
The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line..
Stem Cell Res
38:
101453
2019
view publication
Hosseini Far, H, Patria, YN, Motazedian, A, Elefanty, AG, Stanley, EG, Lamandé, SR, Bateman, JF.
Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing..
Stem Cell Res
37:
101449
2019
view publication
Tian, P, Abberton, K, Elefanty, A, Stanley, E, Hollands, J, Thompson, L, Elwood, N.
PRODUCTION OF iPSCs FROM A SMALL VOLUME OF CRYOPRESERVED HUMAN UMBILICAL CORD BLOOD BUFFY COAT UNDER “GMP-COMPLIANT” CONDITIONS.
Cytotherapy
21(5)
:
s13 -s14
2019
view publication